Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Stoke Therapeutics Inc 45 WIGGINS AVENUE BEDFORD MA 01730 USA

www.stoketherapeutics.com Employees: 170 P: 781-430-8200

Sector:

Medical

Description:

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 1,943,110
Enterprise Value, $K 1,858,400
Shares Outstanding, K 59,151
Float, K 53,532
% Float 90.50%
Short Interest, K 13,384
Short Float 22.63%
Days to Cover 14.48
Short Volume Ratio 0.85
% of Insider Shareholders 9.50%

Financials:

Annual Sales, $ 184,420 K
Annual Net Income, $ -6,890 K
Last Quarter Sales, $ 1,400 K
Last Quarter Net Income, $ -57,930 K
EBIT, $ -20,590 K
EBITDA, $ -19,950 K

Growth:

1-Year Return 340.64%
3-Year Return 294.36%
5-Year Return -16.48%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.97 on 03/16/26
Next Earnings Date 05/12/26
Earnings Per Share ttm 0.85
EPS Growth vs. Prev Qtr -49.23%
EPS Growth vs. Prev Year -438.89%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

STOK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -2.05%
Return-on-Assets % -1.75%
Profit Margin % -3.74%
Debt/Equity 0.00
Price/Sales 10.81
Price/Cash Flow N/A
Price/Book 5.46
Book Value/Share 6.17
Interest Coverage -0.90
60-Month Beta 1.07
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.